NNC0194-0499 + NNC0194-0499 + NC0194-0499
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease
Conditions
Non-alcoholic Fatty Liver Disease
Trial Timeline
Feb 16, 2023 → Jun 13, 2023
NCT ID
NCT05742919About NNC0194-0499 + NNC0194-0499 + NC0194-0499
NNC0194-0499 + NNC0194-0499 + NC0194-0499 is a phase 1 stage product being developed by Novo Nordisk for Non-alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05742919. Target conditions include Non-alcoholic Fatty Liver Disease.
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Fatty Liver Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05742919 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease